- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05368246
Safety and Performance of UCon for the Treatment of the Symptoms of Overactive Bladder (OAB) / Bowel Dysfunction (BD)
Safety and Performance of UCon for the Treatment of the Symptoms of Overactive Bladder (OAB) / Bowel Dysfunction (BD) - An Early Feasibility Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dianna Mærsk Knudsen
- Phone Number: +45 40517712
- Email: dmk@innoconmedical.dk
Study Locations
-
-
-
Odense, Denmark, 5000
- Odense University Hospital
-
-
Aarhus N
-
Aarhus, Aarhus N, Denmark, 8200
- Aarhus University Hospital
-
-
Zealand
-
Herlev, Zealand, Denmark, 2730
- Herlev Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is ≥ 18 years of age.
- Subject is diagnosed with OAB or BD.
- Subject is able to communicate, provide feedback, understand and follow instructions during the course of the study.
- Subject has signed an informed consent.
Exclusion Criteria:
- Subject is medically unstable.
- Subject has an active infection in the genital area.
- Subject has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function).
- Subject is pregnant, nursing or planning a pregnancy (to be confirmed with a negative pregnancy test within 14 days prior to enrolment). Women of childbearing potential must maintain effective contraception* during the study period judged by the investigator.
- Subject is enrolled or planning to enrol in another investigational study or was enrolled in an investigational drug or medical device trial within four weeks to enrolment.
- Subject has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation.
- Subject has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has radiation-induced damage to the pelvic region.
- Subject has addictive behaviour defined as abuse of cannabis, opioids, or other intoxicating drugs.
- Subject does not speak and understand Danish.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional arm
Electrical stimulation to the dorsal genital nerve.
|
The subjects self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of adverse events related to the risks and anticipated adverse device effects associated with the use of UCon.
Time Frame: After 4 and 12 weeks of stimulation (end of study).
|
Characterization of adverse events related to the risks and anticipated adverse device effects associated with the use of UCon during the study period.
|
After 4 and 12 weeks of stimulation (end of study).
|
Ratio of subjects with at least 50% improvement of their OAB/BD symptoms from baseline associated with the use of UCon.
Time Frame: Change from baseline OAB/BD symptoms at 4 and 12 weeks.
|
Urinary urgency is measured by number of urgency episodes/day. Urinary frequency is measured by number of voidings/day. Urgency urinary incontinence is measured by number of leaks preceded by urgency/day. Nocturia is measured by number of voidings/night. Faecal urgency is measured by number of urgency episodes/day. Frequent bowel movements are measured by number of voidings/day. Faecal incontinence (urge/passive) is measured by number of leaks/day. |
Change from baseline OAB/BD symptoms at 4 and 12 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and severity of all adverse events related to the risks and anticipated adverse device effects associated with the use of UCon.
Time Frame: After 4 and 12 weeks of stimulation (end of study).
|
Number of subjects experiencing adverse events related to the risks and anticipated adverse device effects associated with the use of UCon during the study period. Number and severity of adverse events related to the risks and anticipated adverse device effects associated with the use of UCon during the study period. |
After 4 and 12 weeks of stimulation (end of study).
|
Ratio of subjects with improvement in their OAB/BD specific quality-of-life measures from baseline.
Time Frame: Change from baseline QoL at 4 and 12 weeks.
|
For OAB the following is used to assess QoL: "International Consultation on Incontinence Questionnaire Overactive Bladder Module". It contains 4 questions and a higher total score means a worse outcome. For BD a combination of the following is used to assess QoL: "St. Marks incontinence score" and "Rockwood Fecal Incontinence Quality of Life Scale". St. Marks incontinence score contains 7 questions, and a higher total score means a worse outcome. The Rockwood Fecal Incontinence Quality of Life Scale contains 29 questions and a higher total score means a worse outcome. |
Change from baseline QoL at 4 and 12 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter Christensen, Palle Juul Jensens Boulevard 99 DK-8200 Aarhus N
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Digestive System Diseases
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Gastrointestinal Diseases
- Urination Disorders
- Rectal Diseases
- Elimination Disorders
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder, Overactive
- Urinary Incontinence
- Intestinal Diseases
- Enuresis
- Fecal Incontinence
- Urinary Incontinence, Urge
- Nocturia
- Nocturnal Enuresis
Other Study ID Numbers
- DK_FEAS_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Incontinence
-
University of New MexicoRecruitingUrinary Incontinence | Urge Incontinence | Stress Incontinence, FemaleUnited States
-
Juna d.o.o.CompletedFemale Stress Urinary Incontinence | Mixed Incontinence, Urge and Stress
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Stanford...CompletedUrinary Incontinence, Stress | Urge Incontinence | Urinary Stress Incontinence | Stress Incontinence, Urinary | Stress Incontinence | Stress Incontinence, Female | Urgency UrinaryUnited States
-
Ludwig-Maximilians - University of MunichUnknownIncontinence, Overactive Bladder, Stress Urinary IncontinenceGermany
-
San Diego Sexual MedicineRecruitingStress Urinary Incontinence | Urge IncontinenceUnited States
-
Copenhagen University Hospital at HerlevZealand University HospitalTerminatedStress Urinary Incontinence | Urge Urinary IncontinenceDenmark
-
Far Eastern Memorial HospitalRecruitingWomen With Stress Urinary IncontinenceTaiwan
-
ScitonCompletedUrinary Incontinence | Stress Urinary Incontinence | Urge IncontinenceUnited States
-
Université de SherbrookeRecruitingUrinary Incontinence | Urinary Stress Incontinence | Post-Prostatectomy Incontinence | Stress Incontinence, MaleCanada
-
University of ZurichCompletedStress Urinary Incontinence | Urge Urinary Incontinence
Clinical Trials on UCon
-
InnoCon MedicalRecruitingFaecal Incontinence | Faecal Incontinence With Faecal UrgencySpain
-
InnoCon MedicalOdense University Hospital; Aarhus University Hospital; Herlev HospitalRecruitingUrinary Incontinence | Fecal Incontinence | Urinary Incontinence, Urge | Nocturia | Fecal Incontinence With Fecal Urgency | Urinary Frequency More Than Once at Night | Incontinence, Nighttime Urinary | Bowel Disorders FunctionalDenmark